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Abst rac t
Introduction: HLA-C*06 is a major psoriasis genetic risk marker. Recent reports have been focused on the role of 
different polymorphisms within genes involved in the functioning of the epidermal barrier and antigen processing 
in the pathogenesis of psoriasis. Data on the association between genetic variants of LCE3B_LCE3C, CSTA, ERAP1, 
ZAP70 and this dermatosis in the population from Eastern Europe are lacking. 
Aim: To compare the association between known genetic risk markers and psoriasis in a cohort of northern Polish 
patients with psoriasis and healthy controls. 
Material and methods: Based on previous studies’ results, five susceptibility loci: HLA-C, LCE3C_LCE3B, ERAP1, 
ZAP70 and CSTA were selected for genotyping in 148 patients with chronic plaque psoriasis and 146 healthy controls. 
Each patient with this disease was clinically assessed with the Psoriasis Area and Severity Index. 
Results: The study population showed a significant association of psoriasis and a single nucleotide polymorphism 
in the ERAP1 – rs26653 (p = 3.11 × 10–5) and HLA-C*06 allele (p = 1.02 × 10–11) when compared with the control group. 
The presence of HLA-C*06 or rs26653 G allele significantly increased the risk of psoriasis by 2.4 times or twice, 
respectively. Carrying rs26653 C allele considerably decreased the risk of psoriasis by 1.5 times. 
Conclusions: In the context of pathogenesis of psoriasis, our findings might give the evidence on disturbances in 
the proteolytic processing of N-terminal fragments of antigens presented via major histocompatibility complex 
class I to T cells.
Key words: psoriasis, genetic polymorphism, genome-wide association studies.
Introduction
Psoriasis is a common, inflammatory skin disease. It 
affects from 2% to 4% of the Caucasian population [1, 2].
Genetic background plays a key role in the patho-
genesis of psoriasis. It is classified as a complex disease 
with polygenic and multifactorial mode of inheritance. Its 
heterogeneous clinical manifestation depends on interac-
tions between numerous susceptibility genes as well as 
genetic and environmental factors.
Linkage analysis of large family cohorts and ge-
nome-wide association studies (GWAS) have led to iden-
tification of more than 46 susceptibility loci located on 
different autosomal chromosomes. Up to date, the stron-
gest association with psoriasis has been proven in psori-
asis susceptibility 1 (PSORS1) locus on chromosome 6p21 
[2]. The region consists of 300 kilobase-fragment (kb) 
within the major histocompatibility complex class I (MHC 
class I), from corneodesmosin gene (CDSN) to HLA-C. 
Among genes identified in PSORS1 locus, HLA-C*06 allele 
presents the strongest association with psoriasis, which 
has been demonstrated in the studies on various ethnic 
populations [3–9]. As in other disorders characterized 
by polygenic mode of inheritance with a low penetra-
tion power of genes involved in the process, HLA-C*06 is 
responsible for 35–50% of genetic predisposition to the 
early-onset type of psoriasis in Caucasians [10–12].
The latest research results have confirmed the as-
sociation of genes involved in the functioning of the 
epidermal barrier (LCE3 and CSTA) and genetic variants 
involved in the processing of antigens in the context 
of MHC class I and regulation of CD8+ cells activation 
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(ERAP1 and ZAP70) with psoriasis [13–21]. With respect 
to psoriasis pathogenesis, epistasis has been described 
with reference to HLA-C*06 and polymorphisms, such 
as: LCE3C_LCE3B-del and single nucleotide polymor-
phisms (SNPs): rs26653 located within the ERAP1 gene, 
rs17695937 linked to the ZAP70 gene and rs17589 locat-
ed within the CSTA gene [13, 14, 16, 21–25]. On the other 
hand, the reports on interactions of these genetic mark-
ers with HLA-C*06 are inconsistent and differ among eth-
nically diverse populations.
Aim 
In this study, we compared the incidence of HLA-C*06, 
LCE3C_LCE3B-del and three SNPs: rs26653 located within 
the ERAP1 gene, rs17695937 linked to the ZAP70 gene and 
rs17589 located within the CSTA gene in the population of 
patients with psoriasis and healthy controls from northern 
Poland. We compared the coincidence of LCE3C_LCE3B-
del, rs26653, rs17695937 and rs17589 with HLA-C*06 in the 
northern Polish population of patients with psoriasis and 
the control group. We analyzed the relationship between 
HLA-C, LCE3C_LCE3B, CSTA, ERAP1 and ZAP70 genotypes 
and the severity of this dermatosis, provided by Psoriasis 
Area and Severity Index (PASI) score.
Material and methods
Selection of genetic risk markers
The selection of the genetic risk markers included 
into the research was based on previous GWAS and large 
cohort studies’ results demonstrating the strongest as-
sociation with the risk of psoriasis at p < 0.05 [13, 14, 16, 
21, 23, 24, 26, 27].
Sample collection
DNA was obtained from 148 patients with chronic 
plaque psoriasis and 146 unrelated healthy individuals. 
The study population included 79 (53.38%) men and 69 
(46.62%) women. The mean age of the study population 
was 43.3 (range: 18–83) years. Patients with guttate pso-
riasis, pustular psoriasis and psoriatic erythroderma were 
not included in the study. The control group consisted of 
83 (56.64%) men and 63 (43.16%) women, gender- and 
age-matched with the psoriasis patients. The mean age 
of the control group was 42.0 (range: 19–84) years. There 
were neither personal nor family history of psoriasis or 
psoriatic arthritis in the healthy controls. 
All participants provided written informed consent 
and the study was approved by the ethical committee 
of the Medical University of Gdansk (NKBBN/181/2012).
Clinical assessment
The disease severity was evaluated by PASI score, 
which was applied to each patient with psoriasis. The 
index is based on a quantitative assessment of three 
clinical features of psoriatic lesions (erythema, desqua-
mation and infiltration) combined with the skin surface 
area involved. In each patient, PASI score was calculated 
by the same clinical assessor. 
Genotyping
DNA samples were extracted from EDTA-treated pe-
ripheral blood, using a modified non-organic method by 
Lahiri and Nurnberger [28]. The yield and purity of DNA 
were checked by measuring absorbance at 260 nm.
HLA-C*06 genotypes were determined by the op-
timized three-step procedure. Polymerase chain reac-
tion (PCR) with sequence-specific primers (PCR-SSP) 
was used for specific detection of HLA-C*06. PCR with 
analysis of restriction fragment length polymorphism 
(PCR-RFLP) was used to distinguish between HLA-C*06 
homozygous and heterozygous subjects. Homozygous 
genotypes were additionally analyzed for nonspecific di-
gestion by PCR-SSP [29, 30]. The sequences of primers 
used for genotyping of HLA-C*06 (HLA-CF and HLA-CR) 
are presented in Table 1.
Alleles with LCE3C_LCE3B-del were identified by 
PCR with evaluation of amplified fragment length poly-
morphism (PCR-AFLP), described in the study of de Cid 
et al. [14]. Three different primers were used for the reac-
tion (Table 1). A specific product of 240 base pairs (bp) in 
length without the deletion was amplified with LCE3C_F 
and LCE3C_R primers. LCE3C_LCE3B-del allele of 199 bp in 
length was detected by LCE3C_F and LCE3CR2D primers.
After optimization of temperature of hybridization of 
specific primers used to detect SNPs within the ERAP1 
and the CSTA genes and linked to the ZAP70 gene, dis-
Table 1. Sequences of primers used for genotyping of 
HLA-C*06, LCE3C_LCE3B-del, ERAP1, ZAP70 and CSTA 
polymorphisms
Primer name Primer sequence
HLA-CF 5’TTGAGGATTCTCCACTCCCCTGAG3’
HLA-CR 5’CTGTGCCTGGCGCTTGTACTT3’
LCE3C_F 5’TTTGGAGCATGTTGTCAGGA3’
LCE3C_R 5’AGGGTTAGGCACAGGGAACT3’
LCE3CR2D 5’CATCCCAGGGATGCTGCATG3’
ERAP1-FC 5’GCAGTGCAATTTGCTCCTAAC3’
ERAP1-FG 5’GCAGTGCAATTTGCTCCTAAG3’
ERAP1-R 5’TGGGGAACCACGAAAGTAG3’
ZAP70-FA 5’CCTTCGGGGAGATATTTTTCA3’
ZAP70-FG 5’CTTCGGGGAGATATTTTCCG3’
ZAP70-R 5’GCTGGACGCTCATTTCTT3’
CSTA-FC 5’GAAGAAAAAACAAATGAGACTGAC3’
CSTA-FT 5’GAAGAAAAAACAAATGAGACTGAT3’
CSTA-R 5’TGAGAGTCCACCACTTG3’
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crimination of rs26653, rs17589 and rs17695937 alleles 
was performed by PCR-SSP method (Table 1).
In order to ensure quality control in all cases, a nega-
tive non-template control as well as an internal positive 
control of amplification were used to eliminate genotype 
mistakes.
The PCR products were analyzed by polyacrylamide 
gel electrophoresis and stained with silver.
Statistical analysis
No deviations from Hardy-Weinberg equilibrium were 
found. The frequencies of genetic variants and genotypes 
of HLA-C, LCE3C_LCE3B, CSTA, ERAP1 and ZAP70 in pa-
tients with psoriasis and healthy controls were compared 
with the use of Fisher’s exact test for 2 × 2 contingency 
tables and c2 test for large tables. The analysis of co-
incidence of selected psoriasis susceptibility markers 
with HLA-C*06 was performed by Fisher’s exact test. 
The relationship between mean PASI score and studied 
genotypes was calculated by U Mann-Whitney test. The 
calculations were performed with the use of Statistica 
12 package (StatSoft Inc.). Relative risks (RRs) and their 
95% confidence intervals (CIs) were estimated with the 
use of MedCalc 16 (MedCalc Software bvba). Relative risk 
is defined as a ratio of probability of developing psoriasis 
in carriers of the tested allele to probability of develop-
ing the disease in non-carriers of the allele and is given 
by the following formula: (a/(a + b))/(c/(c + d)), where 
a is the number of carriers who developed psoriasis, 
b is the number of carriers who did not develop psoriasis, 
c is the number of non-carriers who developed psoriasis 
and d is the number of non-carriers who did not develop 
psoriasis.
Results
In the population of patients with psoriasis studied 
in this work, 296 alleles were genotyped for HLA-C*06. 
There were 101 alleles with HLA-C*06 (34.1%), whereas 
in 195 (65.9%) HLA-C*06 was not identified. In the con-
trol group, 292 alleles were genotyped for HLA-C*06. In 
32 alleles HLA-C*06 was observed (11.0%), whereas in 
260 (89.0%) HLA-C*06 was not present. The frequency 
of HLA-C*06 allele was significantly higher in the group of 
patients with psoriasis compared with the control group 
(p = 1.02 × 10–11). In the group of patients with psoriasis, 
296 alleles were genotyped for LCE3C_LCE3B-del. One 
hundred eighty-one (61.1%) alleles presented LCE3C_
LCE3B-del, whereas in 115 (38.9%) the deletion was not 
detected. In healthy controls, 292 alleles were genotyped 
for LCE3C_LCE3B-del. In 167 (57.2%) alleles LCE3C_LCE3B-
del was identified, whereas in 125 (42.8%) it was not 
present. The results did not reveal a statistically signifi-
cant difference between patients with psoriasis and the 
control group in LCE3C_LCE3B-del frequency (p = 0.356).
In the group of patients with psoriasis, 254 alleles 
were genotyped for rs26653 G and rs26653 C at ERAP1. 
In 210 (82.7%) alleles rs26653 G was identified, whereas 
in 44 (17.3%) alleles rs26653 C was detected. In the con-
trol group, 202 alleles were genotyped for rs26653 G and 
rs26653 C at ERAP1. In 132 (65.3%) alleles rs26653 G was 
observed, whereas in 70 (34.7%) alleles rs26653 C was 
present. Psoriatic patients presented a significantly high-
er incidence of rs26653 G allele compared with healthy 
individuals, whereas a statistically significant higher fre-
quency of rs26653 C allele was observed in the control 
group compared with the group of patients with psoria-
sis (p = 3.11 × 10–5). 
There were no significant differences between pa-
tients with psoriasis and the control group in rs17589 
alleles at CSTA (p = 1.00) and CSTA genotype frequen-
cies (p = 0.193). Statistically significant differences be-
tween patients with psoriasis and the control group in 
rs17695937 alleles at ZAP70 (p = 0.300) and ZAP70 geno-
type frequencies (p = 0.468) were not found. 
Psoriatic patients presenting heterozygous LCE3C_
LCE3B-del genotype showed a statistically higher mean 
PASI score compared to patients having both copies of 
the LCE3B and LCE3C. There was a statistically higher 
mean PASI score in patients with psoriasis carrying at 
least one rs17695937 G copy at ZAP70 (either heterozy-
gous or homozygous) compared with the patients with-
out this allele. Psoriatic patients presenting homozygous 
rs17695937 A genotype demonstrated a statistically 
lower PASI score compared to the patients with hetero-
zygous ZAP70 genotype. There were no statistically sig-
nificant differences in mean PASI score between ERAP1 
and CSTA genotypes. Table 2 presents the relationship 
between mean PASI score and different genotypes of 
HLA-C, LCE3C_LCE3B, CSTA, ERAP1 and ZAP70.
The group of individuals carrying HLA-C*06 allele 
demonstrated a statistically higher frequency of rs26653 
G allele at ERAP1 in the population of patients with pso-
riasis compared with the control group. In HLA-C*06-
positive group, a statistically higher incidence of rs26653 
C allele at ERAP1 was observed in the control group 
compared with patients with psoriasis. In the group of 
individuals carrying at least one copy of HLA-C*06, no 
significant differences between patients with psoriasis 
and healthy controls in the frequencies of LCE3C_LCE3B-
del, CSTA and ZAP70 alleles were found. Table 3 demon-
strates the comparison of frequencies of LCE3C_LCE3B-
del, rs17589 at CSTA, rs26653 at ERAP1, rs17695937 at 
ZAP70 in HLA-C*06-positive group in the population of 
patients with psoriasis and healthy individuals. Carrying 
at least one copy of HLA-C*06 increased significantly the 
risk of psoriasis 2.4 times in the study population. Carry-
ing an allele other than HLA-C*06 allele decreased signifi-
cantly the risk of psoriasis twice in the study population. 
Individuals with rs26653 G allele at ERAP1 demonstrated 
a significantly higher risk of psoriasis development com-
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Table 2. The relationship between mean PASI score and different genotypes of HLA-C, LCE3C_LCE3B, CSTA, ERAP1 and 
ZAP70
Gene Genotypes compared Mean PASI score P-value*
Group 1 Group 2 Group 1 Group 2
HLA-C C*06 (+) C*06 (–) 17.7 14.6 0.13
Non-C*06 (+) Non-C*06 (–) 16.2 31.4 0.04
C*06/C*06 Heterozygotes 31.4 17.1 0.05
Non-C*06/non-C*06 Heterozygotes 14.6 17.1 0.20
LCE3C_LCE3B del(+) del(–) 17.2 13.8 0.06
wt(+) wt(–) 17.2 15.8 0.46
del/del Heterozygotes 15.8 18.2 0.15
wt/wt Heterozygotes 13.8 18.2 0.03
CSTA C(+) C(–) 16.6 18.0 0.61
T(+) T(–) 17.0 15.3 0.64
CC Heterozygotes 15.3 16.9 0.69
TT Heterozygotes 18.0 16.9 0.66
ERAP1 G(+) G(–) 16.7 15.2 0.79
C(+) C(–) 15.8 16.9 0.89
GG Heterozygotes 16.7 16.6 0.73
CC Heterozygotes 15.2 16.6 0.89
ZAP70 G(+) G(–) 18.5 15.4 0.03
A(+) A(–) 16.6 18.7 0.97
GG Heterozygotes 18.7 18.5 0.74
AA Heterozygotes 15.4 18.5 0.02
*U Mann-Whitney test.
Table 3. Comparison of LCE3C_LCE3B, CSTA, ERAP1 and ZAP70 allele frequencies in the HLA-C*06-positive group in the 
population of psoriatic patients and controls
Parameter HLA-C*06(+) (n) LCE3C_LCE3B-del (n) Non-LCE3C_LCE3B-del (n) P-value*
Psoriasis 97 0.603 0.397 0.770
Control 32 0.578 0.422
HLA-C*06(+) (n) rs17589 C (n) rs17589 T (n)
Psoriasis 96 0.547 0.453 0.885
Control 32 0.531 0.469
HLA-C*06(+) (n) rs26653 G (n) rs26653 C (n)
Psoriasis 85 0.800 0.200 0.019855
Control 23 0.630 0.370
HLA-C*06(+) (n) rs17695937 G (n) rs17695937 A (n)
Psoriasis 97 0.242 0.758 0.301
Control 32 0.172 0.828
*Fisher’s exact test.
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bined by 2.0 in the study population. Carrying rs26653 
C allele at ERAP1 significantly decreased the risk of pso-
riasis 1.5 times in the analyzed population. Table 4 pres-
ents a relative risk score of psoriasis in genetic markers 
in HLA-C, LCE3C_LCE3B, CSTA, ERAP1 and ZAP70 in the 
study population.
Discussion
In the context of disorders with polygenic mode of 
inheritance, where single genes present a modest impact 
on the phenotype, GWAS became an extremely useful 
tool used for molecular analysis. With genotyping of 
hundreds of thousands of polymorphisms it led in the 
last decade to identification of novel genetic risk markers 
associated with psoriasis. The latest results of genetic 
analyses including patients with psoriasis from north-
ern Poland have demonstrated the association of the 
–2518 A/G monocyte chemoattractant protein-1 (MCP-1) 
and –403 G/A regulated on activation, normal T-cell ex-
pressed and secreted (RANTES) promoter gene polymor-
phisms with an increased risk of psoriasis and suggested 
the influence of polymorphisms in the Toll-like receptor 2 
(TRL2) and Toll-like receptor 9 (TLR9) genes on the clinical 
manifestation of this dermatosis [31, 32]. Among differ-
ent genetic markers identified in the context of psoria-
sis susceptibility, HLA-C*06 still presents the strongest 
association with the early-onset type of the disease in 
Caucasians [3, 7, 8, 33–35]. This fact has been also con-
firmed by the studies performed in the Polish population 
of patients with psoriasis from north and south regions 
[8, 29, 36]. On the other hand, psoriasis susceptibility 
genes located within PSORS1 locus are estimated to be 
responsible for less than 50% of genetic predisposition 
to the disease, which indicates the presence of other 
markers outside the MHC region, which may predispose 
to psoriasis [10–12]. In this study, the frequency of HLA-
C*06 was found to be significantly higher in patients with 
psoriasis than in the control group, which is in agreement 
with other cohorts’ results, as well as with earlier studies 
performed in the northern Polish population [3–9, 36]. 
The incidence of HLA-C*06 in the group of psoriatic pa-
tients involved in this research was 65.5% which does not 
differ from other findings [37–39]. 
Recent GWAS results showed the association of novel 
genetic markers involved in the skin barrier functioning 
with psoriasis. Numerous observations within ethnically 
diverse populations have proven a common deletion in 
LCE3B and LCE3C genes (LCE3C_LCE3B-del) to predispose 
to psoriasis [14, 17, 19, 20, 23, 40]. Our study is the first 
analysis on frequency of LCE3C_LCE3B-del in patients 
with psoriasis from Eastern Europe. Herein a higher in-
cidence of LCE3C_LCE3B-del in the population of psori-
atic patients compared to the control group was found 
although the difference was not statistically significant. 
Our findings revealed a significant higher mean PASI 
score in patients carrying LCE3C_LCE3B-del compared to 
the patients with both copies of LCE3B and LCE3C genes. 
This might refer to the influence of LCE3C_LCE3B-del on 
the clinical course of the disease. There are only a few 
reports on higher frequency of LCE3C_LCE3B-del in pa-
tients with the early-onset type of the disease, but the 
relationship with PASI score has never been analyzed so 
far [20, 24].
Another protein arranged in the process of cornified 
envelope formation and proper skin barrier functioning is 
cystatin A, encoded by CSTA gene on 3q21 chromosome. 
Vasilopoulos et al. investigated three genetic markers in 
the CSTA gene, but the strongest effect on the psoriasis 
risk was found in rs17589 (p < 0.001) [21, 25]. A higher 
expression of cystatin A was also observed in psoriasis 
plaques compared to healthy skin [41]. Our research is 
the first study on frequency of rs17589 at CSTA in the 
population of patients with psoriasis from Eastern Eu-
rope. No differences in frequencies of genetic variants 
in CSTA gene between psoriatic patients and the control 
group were found. These observations are in agreement 
with the results reported by Samuelsson et al. [42]. Dif-
ferent findings might be explained by genetic variations 
between Polish and British populations, which needs 
further research. 
Numerous SNPs within the ERAP1 gene have been 
proven to have an effect on genetic predisposition to 
psoriasis, but the strongest association with the disease 
in the European population has been found in rs26653 
marker (p = 0.00006) [26]. These observations were 
confirmed by Tang et al. for the Chinese population (p = 
5.27 × 10–12) [27]. Various polymorphisms at ZAP70 were 
analyzed in the context of predisposition to psoriasis [13, 
43]. The strongest association with the disease has been 
shown by Strange et al. in rs17695937 marker (p = 2.37 
Table 4. Relative risk score for each of the analyzed 
psoriasis genetic markers in the case-control samples 
from northern Poland 
Genotype Relative risk 95% CI
HLA-C*06 (+) 2.4327 1.8970–3.1197
Non-HLA-C*06 (+) 0.4966 0.4422–0.5576
LCE3C_LCE3B-del (+) 1.0898 0.7848–1.5134
Non-LCE3C_LCE3B-del (+) 0.8849 0.7026–1.1145
rs17589 C (+) 0.7093 0.4843–1.0388
rs17589 T (+) 0.8540 0.6383–1.1425
rs26653 G (+) 1.9865 1.1364–3.4726
rs26653 C (+) 0.6522 0.4923–0.8640
rs17695937 G (+) 1.1343 0.9035–1.4241
rs17695937 A (+) 0.7526 0.4225–1.3407
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× 10–7) [13]. The proteins encoded by ERAP1 and ZAP70 
genes play an important role in antigen processing and 
its presentation in the context of MHC class I that results 
in the activation of CD8+ lymphocytes. What is more, the 
study by Strange et al. proved an association of SNPs 
at ERAP1 (rs27524) and linked to ZAP70 (rs17695937) 
with psoriasis only in the group of patients carrying 
HLA-C*06 allele, which is evidence on interaction be-
tween these genetic markers [13]. Our report is the first 
study on frequency of genetic risk variants at ERAP1 and 
ZAP70 genes in the population of patients with psoriasis 
from Eastern Europe. We found a significant higher fre-
quency of rs26653 G allele in the group of psoriatic pa-
tients compared with the healthy controls. On the other 
hand, rs26653 C allele was significantly more frequent 
among healthy individuals compared with the patients 
with psoriasis, which may indicate the protective effect 
of this genetic marker. The evaluation of frequencies 
of particular ERAP1 genotypes, revealed a significant 
higher incidence of homozygous rs26653 G genotype 
in the population of patients with psoriasis compared 
with the control group. Up to date, this has been the first 
report in the literature. A significant higher mean PASI 
score was observed in patients with psoriasis carrying 
at least one copy of rs17695937 G allele compared to the 
patients with homozygous genotype of rs17695937 A. 
On the contrary, patients with two copies of rs17695937 
A allele presented a significant lower mean PASI score 
compared to the patients with one copy of rs17695937 G 
allele. These findings may indicate the existence of the 
protective effect of rs17695937 A resulting in less severe 
course of the disease, but only in the group of patients 
carrying both copies of this allele. On the other hand, the 
presence of rs17695937 G allele may be considered as 
a negative prognostic factor, correlated with more severe 
psoriasis clinical course. 
The results of single reports on interaction between 
polymorphisms within the ERAP1 gene and the major 
psoriasis susceptibility allele – HLA-C*06 were not con-
firmed in the present study [13, 24]. Although we found 
a statistically significant difference between the patients 
with psoriasis and the control group in the frequencies of 
ERAP1 alleles in the population of C*06-positive individu-
als, the difference was also shown in the whole group 
of subjects without limitation to HLA-C*06 carriers. This 
result presents a lack of interaction between ERAP1 and 
HLA-C*06, which might be explained by a low number 
of healthy individuals carrying HLA-C*06 in the control 
group. To compare, the analysis made by Strange et al., 
which is evidence of such interaction, included 2.622 pso-
riasis patients and 5667 healthy controls [13].
In the study population, rs26653 G allele proved to 
be almost as strong psoriasis genetic risk marker as 
HLA-C*06. Although in the present research, we did not 
show a statistically significant interaction between these 
genetic variants, the results seem to be reflected in the 
biological functions of the proteins encoded by HLA-C*06 
and ERAP1. Based on our findings, we assume that ge-
netically determined change in ERAP1 and Cw6 protein 
function in patients with psoriasis is related and might 
play an important role in the pathogenesis of the dis-
ease. One of the current hypotheses on the induction 
of the psoriatic process is based on presentation of an 
unknown antigen to CD8+ cells via Cw6 molecules. We 
consider that the excessive activation of CD8+ T-cells is 
due to the presentation of proteins in the context of MHC 
class I, which N-terminal fragments underwent previous-
ly an abnormal proteolysis catalyzed by ERAP1.
Conclusions
Among genetic markers (analyzed in the present 
study): HLA-C*06, LCE3C_LCE3B-del, rs17589 located 
within the CSTA gene, rs26653 located within the ERAP1 
gene, rs17695937 linked to the ZAP70 gene, we con-
firmed the strong association of HLA-C*06 and rs26653 
G alleles with the risk of psoriasis in the northern Pol-
ish population. Our findings suggest a protective role of 
rs26653 C allele at ERAP1 in the study population. None 
of analyzed CSTA alleles presented an effect on genetic 
predisposition to psoriasis. It has been shown that se-
verity of the disease might be determined by HLA-C, 
LCE3C_LCE3B and ZAP70 genotypes, which has not been 
previously reported. 
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